Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Profile
Plotinus's Profile
Displaying 51-100 of 645 result(s).
CYDY CytoDyn Inc
02/12/2025 9:18:25 AM
Stumbled on this and while dated 20 (6)
CYDY CytoDyn Inc
02/06/2025 7:16:42 PM
While multifactorial in origin Card (9)
CYDY CytoDyn Inc
02/04/2025 10:43:09 AM
Love the Johnny Thunder reference. (10)
CYDY CytoDyn Inc
01/22/2025 1:59:33 PM
Respert sold his wine cellar and we (4)
CYDY CytoDyn Inc
01/18/2025 10:39:57 AM
A reasonable a-priori assumption is (16)
CYDY CytoDyn Inc
01/07/2025 8:43:19 PM
Without descending into undo specul (14)
CYDY CytoDyn Inc
12/29/2024 8:17:41 PM
Came across this recently posted (N (8)
CYDY CytoDyn Inc
12/19/2024 10:13:53 AM
Diastolic dysfunction is indeed a m (11)
CYDY CytoDyn Inc
12/17/2024 3:30:41 PM
Agreed…press release would be app (6)
CYDY CytoDyn Inc
12/17/2024 3:05:33 PM
“The results from this preliminar (19)
CYDY CytoDyn Inc
12/17/2024 2:46:42 PM
“So they need something like Lero (6)
CYDY CytoDyn Inc
12/17/2024 1:05:21 PM
Robust newsy update from Cytodyn th (37)
CYDY CytoDyn Inc
12/06/2024 6:13:19 PM
If you go to Max’ LinkedIn pay so (12)
CYDY CytoDyn Inc
12/06/2024 5:22:12 PM
It is definitely good news IMHO. Li (13)
CYDY CytoDyn Inc
12/02/2024 4:36:41 PM
Cancer really sucks and cancer asso (5)
CYDY CytoDyn Inc
11/25/2024 10:47:15 PM
3 years sounds crazy because it isâ (5)
CYDY CytoDyn Inc
11/25/2024 10:38:19 PM
OHM20 has mentioned the other key f (6)
CYDY CytoDyn Inc
11/25/2024 10:11:19 PM
No way this trial takes a year to e (22)
CYDY CytoDyn Inc
11/25/2024 11:22:00 AM
I tend to agree and you have to let (18)
CYDY CytoDyn Inc
11/23/2024 9:42:42 AM
I agree it would have been best to (5)
CYDY CytoDyn Inc
11/22/2024 12:04:59 PM
Yes… I am blocked out. I sent an (2)
CYDY CytoDyn Inc
11/22/2024 10:03:18 AM
The Leronlimab doses are listed on (4)
CYDY CytoDyn Inc
11/22/2024 9:42:26 AM
Oops…3 hours early
CYDY CytoDyn Inc
11/22/2024 9:35:51 AM
I am unable to get into the Cytodyn
CYDY CytoDyn Inc
11/22/2024 7:18:44 AM
Cardamine, just to clarify that in (13)
CYDY CytoDyn Inc
11/21/2024 4:06:57 PM
A couple of comments after attendin (24)
CYDY CytoDyn Inc
11/14/2024 9:27:34 AM
It would be of interest to see the (25)
CYDY CytoDyn Inc
11/13/2024 7:16:04 PM
Thanks for the link Drano, the edit (19)
CYDY CytoDyn Inc
11/04/2024 12:06:41 PM
I am looking for those details also (1)
CYDY CytoDyn Inc
11/04/2024 10:12:25 AM
On the timing, not surprised, expec (5)
CYDY CytoDyn Inc
11/04/2024 9:03:44 AM
I checked clinical trials.gov just (10)
CYDY CytoDyn Inc
11/01/2024 9:23:29 AM
I had a thought to complete the REC (20)
CYDY CytoDyn Inc
10/30/2024 8:38:40 AM
There are going to be many more mil (5)
CYDY CytoDyn Inc
10/20/2024 1:55:01 PM
Intuition…advantage women…much (1)
CYDY CytoDyn Inc
10/20/2024 1:51:39 PM
“The neurons in his right hemisph (6)
CYDY CytoDyn Inc
10/20/2024 12:40:36 PM
I would say sex is a variable on th (4)
CYDY CytoDyn Inc
10/14/2024 4:08:06 PM
What they might be suggesting needs (9)
CYDY CytoDyn Inc
10/06/2024 9:55:54 AM
I will just add this footnote to yo (15)
CYDY CytoDyn Inc
10/06/2024 9:42:52 AM
I think the board here should under (26)
CYDY CytoDyn Inc
10/04/2024 11:59:54 AM
“I don’t see this CEO getting s (17)
CYDY CytoDyn Inc
09/25/2024 1:01:35 PM
CRP reductions with Leronlimab in t (4)
CYDY CytoDyn Inc
09/24/2024 4:12:07 PM
“Leronlimab monotherapy (700 mg) (21)
CYDY CytoDyn Inc
09/20/2024 9:04:59 AM
It remains to let the results of th (28)
CYDY CytoDyn Inc
09/14/2024 9:11:11 PM
I was living in Seattle, enrolled i (15)
CYDY CytoDyn Inc
09/06/2024 10:23:13 AM
On February 1, Cytodyn announced in (4)
CYDY CytoDyn Inc
08/27/2024 9:32:30 AM
I was just looking at the SMC websi (17)
CYDY CytoDyn Inc
08/26/2024 2:29:01 PM
“How about conjugating LL with a (9)
CYDY CytoDyn Inc
08/26/2024 10:17:10 AM
“Not even a pre-clinical murine s (4)
CYDY CytoDyn Inc
08/26/2024 7:25:41 AM
The FDA would likely not approve a (3)
CYDY CytoDyn Inc
08/24/2024 7:20:46 PM
I have a hunch that the mouse MASH (16)
Go to page:
  • << First
  • < Previous
  • 1
  • 2
  • Next >

Recent Articles

  • Grayscale Unveils Innovative Staking ETF for Solana Investors
  • Major Insider Trading Activity Revealed at Pegasystems
  • SVA APP BOL's IPO: Transforming Brand Promotion Futures
  • Rigetti Computing Inc Stocks Experience Noteworthy Surge Today
  • North Square Investments Celebrates Major Fund Growth Milestone
  • NVIDIA's Standout Performance in the Semiconductor Landscape
  • Microsoft: An In-Depth Look at Software Competitors
  • Analyzing Recent Trends in Dell Technologies Inc's Short Selling
  • Exploring Market Trends for Equifax Inc: A Stock Analysis
  • Understanding Market Sentiment Around Axon Enterprise Inc
  • Pegasystems Insider Transaction: Stock Options Worth $2.80M
  • Kenneth Stillwell's Option Exercise: Insights for Investors at Pegasystems
  • Hargreave Hale AIM VCT PLC Completes Share Cancellation
  • Richard D. Kinder's $25.96 Million Investment in KMI Stock
  • Kristine Melachrino’s Major Stock Sale: Insights and Impact
  • Alpha Omega Celebrates Growth with Washington Business Journal Honor
  • Understanding Recent Insider Selling: Impact on Dayforce Inc.
  • Chongqing Celebrates Global Urban Future on World Cities Day
  • Jungbunzlauer's Tricalcium Citrate Sets New Standards in Pharma
  • Exploring the Growth of Ascendis Pharma Over a Decade
  • Discover the Growth of Your Investment in US Foods Holdings
  • Breakthrough in Tablet Manufacturing with Jungbunzlauer's TCC
  • Discover Birdie: Your Ultimate AI Golf Trip Planning Assistant
  • Workday's Evolution: Leading the Future of Cloud ERP Finance
  • New Ad Campaign by Save America Movement Challenges Tariffs
  • Kingsford® Unveils Slow Burn Fragrance with Jason Kelce
  • Innovative Solution for PVC Pipe Recycling by Inventor
  • Trousdale Ventures Earns Spot on Exclusive Investors List
  • Discovering the Mind: Consello Launches Grey Matter Podcast
  • In-Depth Analysis of Meta Platforms' Competitive Landscape
  • Celebrating Heroes of Learning Disabilities: NCLD's Benefit
  • JD.com Inc: Insights on Stock Performance and Market Trends
  • Amazon.com: A Detailed Look at Its Sway in Retail Markets
  • Apple's Competitive Edge in Technology Hardware Industry Insights
  • Taiwan Semiconductor's Options Activity: What Investors Need to Know
  • Diving Deep into Oklo's Options Surge and Market Position
  • Insights into Goldman Sachs Group’s Strong Options Activity
  • Healthcare Costs: Urgent Need for Affordable Insurance Solutions
  • Global Pharmaceutical Market Growth Driven by Aging Population Needs
  • Enhancing Reliability: Penguin Solutions’ New Platform
  • Growth Forecast for Plastic Compounding Market to 2034
  • Garmin’s Q3 Performance Surprises Investors Amidst Challenges
  • Enterprise Products Partners: What to Expect This Quarter
  • Unlocking High Leverage Trading Without Overhead Costs
  • Eli Lilly's Upcoming Earnings: What Investors Should Know
  • Mutuum Finance (MUTM) Achieves Major Milestone in DeFi Growth
  • Cloudflare's Upcoming Earnings: What Investors Should Expect
  • FirmPilot 2.0 Revolutionizes Legal Marketing with AI Innovations
  • LG Electronics' Kitchen Appliances Shine at Good Housekeeping Awards
  • Vishay Intertechnology Unveils Cutting-Edge 150 W Space Transformers
  • Home - Investors HangoutHome

  • Mailbox - Investors HangoutMailbox

  • Boards - Investors HangoutBoards

  • Favorites - Investors HangoutFavorites

  • Whats Hot! - Investors HangoutWhats Hot!

  • More - Investors HangoutMore

  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site